Categories: Health

Vnzymes Opens New European Office in Frankfurt to Accelerate Innovation in Animal Nutrition and Sustainable Agriculture

FRANKFURT, Germany, Nov. 15, 2025 (GLOBE NEWSWIRE) — Vnzymes, the new brand and European subsidiary of VTR Biotech Group, today officially announced the grand opening of its office in Frankfurt, marking a significant milestone in the company’s global expansion. The move underscores Vnzymes’ commitment to driving innovation in animal nutrition, industrial enzymes, and sustainable agriculture across Europe and beyond.

Founded on the strong foundation of VTR Biotech’s global resources and scientific expertise, Vnzymes deliver biosolutions that promote sustainability, efficiency, and responsibility. The Frankfurt office will serve as the hub for the company’s European operations, supporting research and development, technical services, and local market development tailored to regional needs.

For more than 30 years, VTR Biotech has been dedicated to its mission of ‘Bioscience Impact Tomorrow’, advancing the research, development, and application of enzyme preparations, biosynthetic products, and plant extracts,” said Cindy Chen, CEO of Vnzymes. “With the launch of Vnzymes in Europe, we are creating a platform that not only leverages our global expertise but also addresses local market requirements in animal nutrition and health, delivering real value to our partners, clients, and the communities we serve”.

Starting from Asia, VTR Biotech has established a global sales network across more than 60 countries and regions. Collaborating with research institutions and partners worldwide, the company has played a pivotal role in transforming animal nutrition, health, and sustainable agriculture through biotechnology.

The establishment of Vnzymes in Frankfurt represents a strategic step in VTR Biotech’s international growth. The European office will focus on accelerating innovation in animal nutrition and health, bio-agriculture, and plant extracts, providing sustainable and efficient biosolutions designed to benefit both humanity and the planet.

“As the global market evolves, true globalization is about more than expanding into new territories,” Dr Wang Yufeng, the senior technical director of Vnzymes added. “It’s about delivering meaningful innovations that meet local needs while maintaining a global perspective. Vnzymes is uniquely positioned to achieve this in Europe.”

Vnzymes’ core product portfolio includes xylanase and phytase enzymes, which enhance nutrient digestibility, improve phosphorus utilization, and support intestinal health and growth performance in livestock, as well as natural feed additives derived from Macleaya cordata, which boost feed intake, strengthen immunity, enhance antioxidant capacity, and promote sustainable and healthy animal production.

Media contact

Contact Name: Cindy Chen

Company Name: Vnzymes

Website: www.vnzymes.com

Email: info@vnzymes.com

Disclaimer: This content is provided by Vnzymes. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or business advice. All investments carry inherent risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any inaccuracies, misrepresentations, or financial losses resulting from the use or reliance on the information in this press release. Speculate only with funds you can afford to lose. In the event of any legal claims or concerns regarding this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without warranties or representations of any kind, express or implied. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained herein. Any complaints, copyright issues, or inquiries regarding this article should be directed to the content provider listed above.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/9a669e0e-9a7f-4189-a92a-158ecfd0e66d
https://www.globenewswire.com/NewsRoom/AttachmentNg/ef99d83b-df6b-49f9-870a-58a9403fa172
https://www.globenewswire.com/NewsRoom/AttachmentNg/4b9cd0ca-9e29-4f99-99d3-df934aea9edf
https://www.globenewswire.com/NewsRoom/AttachmentNg/1a420993-debb-4277-87c0-2707fe114079
https://www.globenewswire.com/NewsRoom/AttachmentNg/8012bda3-0b3d-4366-a1c3-65e3663069df

GlobeNews Wire

Recent Posts

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in…

7 hours ago

ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026

– Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC…

7 hours ago

Fobi AI Provides Corporate Update Regarding FFCTO Revocation Process and Q3 Interim Filings

May 29, 2026 21:18 ET  | Source: Fobi AI Inc. VANCOUVER, BC, May 29, 2026…

14 hours ago

Crypto News Today: AlphaPepe Presale Stage 17 Nears Sell Out While XRP Price Prediction Eyes $7.00

MONACO, May 29, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe as…

14 hours ago